Clinical Scorecard: Shape-Changing IOL Shows Durability
At a Glance
| Category | Detail |
|---|---|
| Condition | Presbyopia and cataract requiring premium intraocular lens (IOL) implantation |
| Key Mechanisms | Two-part modular design with a fluid-filled, shape-changing base responding to natural accommodation and a front optic for refractive correction |
| Target Population | Patients undergoing cataract surgery seeking presbyopia correction |
| Care Setting | Surgical implantation in ophthalmology clinics and surgical centers |
Key Highlights
- Sustained refractive stability within ±0.50 D spherical equivalent over 36 months
- Continuous range of vision from distance through near with functional defocus range of ~5.0 D
- Low complication rates with only one YAG capsulotomy and no lens exchanges or refractive enhancements
Guideline-Based Recommendations
Diagnosis
- Assess patients with cataracts and presbyopia considering premium IOL options
Management
- Consider investigational shape-changing, modular IOL designs like the OmniVu Lens System for accommodating vision correction
- Monitor refractive outcomes and visual acuity post-implantation
Monitoring & Follow-up
- Regular follow-up to evaluate manifest refraction spherical equivalent and refractive cylinder stability
- Assess uncorrected and best-corrected visual acuities at distance, intermediate, and near
- Monitor for posterior capsule opacification and need for YAG capsulotomy
Risks
- Potential for posterior capsule opacification, though reduced by capsular-bag-filling design
- Standard surgical risks associated with IOL implantation
Patient & Prescribing Data
19 patients (29 eyes) with monocular and binocular implantation in a prospective multicenter study
Demonstrated stable refractive outcomes and excellent visual acuity through 36 months with minimal adverse events
Clinical Best Practices
- Utilize modular, shape-changing IOL designs to potentially enhance accommodative response and lens position stability
- Conduct comprehensive visual acuity and refractive assessments over long-term follow-up
- Educate patients on investigational status and expected outcomes of novel premium IOL technologies
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
